GlaxoSmithKline and others (paroxetine) (CE/9531-11) [Archived]
GlaxoSmithKline and others (paroxetine) (CE/9531-11) [Archived]

The following Competition practice note provides comprehensive and up to date legal information covering:

  • GlaxoSmithKline and others (paroxetine) (CE/9531-11) [Archived]
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB (Appeals lodged at the Competition Appeal Tribunal–see GlaxoSmithKline and other v CMA (paroxetine))

ARCHIVED–this archived case hub reflects the position at the date of the decision of 12 February 2016; it is no longer maintained.

See further, timeline, commentary and related cases.

Case facts

OutlineCMA Articles 101 and 102 TFEU/Chapters I and II investigation into GlaxoSmithKline and generic drug producers in relation to pay-for-delay agreements concerning anti-depressant medicines (paroxetine) (Case CE/9531-11).

Appeals lodged at the Competition Appeal Tribunal:
• Generics UK Limited v CMA (1251/1/12/16)
• GlaxoSmithKline PLC v CMA (1252/1/12/16)
• (1) Xellia Pharmaceuticals APS (2) Alpharma LLC v CMA (1253/1/12/16)
• Actavis UK Limited v CMA (1254/1/12/16)
• Merck KGaA v CMA (1255/1/12/16)

Latest developmentsOn 12 February 2016, the CMA issued its infringement decision and imposed the following fines:
• GSK has been fined £37,606,275
• in relation to GUK's infringement, GUK and Merck KGaA (GUK's former parent) have been fined a total of £5,841,286 (both companies being jointly and severally liable)
• in relation top Alpharma's infringement, Actavis UK Limited (formerly Alpharma Limited), Xellia Pharmaceuticals ApS (formerly Alpharma ApS) and Alpharma LLC (formerly Zoetis Products LLC, Alpharma LLC and Alpharma Inc) have been fined a total of £1,542,860 (all companies being jointly and severally liable).

Also on 12 February 2016, the CMA issued a no grounds for

Popular documents